Cargando…

HDAC inhibitor valproic acid upregulates CAR in vitro and in vivo

BACKGROUND: The presence of CAR in diverse tumor types is heterogeneous with implications in tumor transduction efficiency in the context of adenoviral mediated cancer gene therapy. Preliminary studies suggest that CAR transcriptional regulation is modulated through histone acetylation and not throu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Segura-Pacheco, Blanca, Avalos, Berenice, Rangel, Edgar, Velazquez, Dora, Cabrera, Gustavo
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2007
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2174455/ https://www.ncbi.nlm.nih.gov/pubmed/17892546 http://dx.doi.org/10.1186/1479-0556-5-10

Ejemplares similares

Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines
por: Chavez-Blanco, Alma, et al.
Publicado: (2006)

Valproic Acid and Other HDAC Inhibitors Upregulate FGF21 Gene Expression and Promote Process Elongation in Glia by Inhibiting HDAC2 and 3
por: Leng, Yan, et al.
Publicado: (2016)

Inhibition of leukemic cells by valproic acid, an HDAC inhibitor, in xenograft tumors
por: Zhang, Zhihua, et al.
Publicado: (2013)

Potential repurposing of the HDAC inhibitor valproic acid for patients with COVID-19
por: Pitt, Bertram, et al.
Publicado: (2021)

Influence of the HDAC Inhibitor Valproic Acid on the Growth and Proliferation of Temsirolimus-Resistant Prostate Cancer Cells In Vitro
por: Makarević, Jasmina, et al.
Publicado: (2019)

Resistance after Chronic Application of the HDAC-Inhibitor Valproic Acid Is Associated with Elevated Akt Activation in Renal Cell Carcinoma In Vivo
por: Juengel, Eva, et al.
Publicado: (2013)

In Vivo Screening Using Transgenic Zebrafish Embryos Reveals New Effects of HDAC Inhibitors Trichostatin A and Valproic Acid on Organogenesis
por: Li, Ling, et al.
Publicado: (2016)

Histone Deacetylases (HDAC) Inhibitor—Valproic Acid Sensitizes Human Melanoma Cells to Dacarbazine and PARP Inhibitor
por: Drzewiecka, Małgorzata, et al.
Publicado: (2023)

HDAC2 Inhibitor Valproic Acid Increases Radiation Sensitivity of Drug-Resistant Melanoma Cells
por: Kalal, Bhuvanesh Sukhlal, et al.
Publicado: (2019)

HDAC (Histone Deacetylase) Inhibitor Valproic Acid Attenuates Atrial Remodeling and Delays the Onset of Atrial Fibrillation in Mice
por: Scholz, Beatrix, et al.
Publicado: (2019)

Valproic Acid as a Potential Inhibitor of Plasmodium falciparum Histone Deacetylase 1 (PfHDAC1): An in Silico Approach
por: Elbadawi, Mohamed A. Abdallah, et al.
Publicado: (2015)

HDAC inhibitor valproic acid protects heart function through Foxm1 pathway after acute myocardial infarction
por: Tian, Shuo, et al.
Publicado: (2018)

The Class I HDAC Inhibitor Valproic Acid Strongly Potentiates Gemcitabine Efficacy in Pancreatic Cancer by Immune System Activation
por: Blaauboer, Amber, et al.
Publicado: (2022)

Exposure to valproic acid (VPA) reproduces hdac1 loss of function phenotypes in zebrafish
por: Jones, Alec A., et al.
Publicado: (2023)

Synergistic Antitumor Effects of Novel HDAC Inhibitors and Paclitaxel In Vitro and In Vivo
por: Zuco, Valentina, et al.
Publicado: (2011)

Valproic acid increases CAR T cell cytotoxicity against acute myeloid leukemia
por: Wen, Jingjing, et al.
Publicado: (2023)

In Vitro and In Vivo Radiosensitizing Effect of Valproic Acid on Fractionated Irradiation
por: Chie, Eui Kyu, et al.
Publicado: (2015)

The histone deacetylase inhibitor valproic acid inhibits NKG2D expression in natural killer cells through suppression of STAT3 and HDAC3
por: Ni, Lulu, et al.
Publicado: (2017)

Effects of the Histone Deacetylase Inhibitor Valproic Acid on Human Pericytes In Vitro
por: Karén, Jakob, et al.
Publicado: (2011)

Quantitative in vitro to in vivo extrapolation for developmental toxicity potency of valproic acid analogues
por: Chang, Xiaoqing, et al.
Publicado: (2022)

HDAC inhibitor apicidin suppresses murine oral squamous cell carcinoma cell growth in vitro and in vivo via inhibiting HDAC8 expression
por: Ahn, Mee-Young
Publicado: (2018)

HDAC Inhibitor L-Carnitine and Proteasome Inhibitor Bortezomib Synergistically Exert Anti-Tumor Activity In Vitro and In Vivo
por: Huang, Hongbiao, et al.
Publicado: (2012)

L-Carnitine Is an Endogenous HDAC Inhibitor Selectively Inhibiting Cancer Cell Growth In Vivo and In Vitro
por: Huang, Hongbiao, et al.
Publicado: (2012)

In vitro and in vivo anti−Toxoplasma activities of HDAC inhibitor Panobinostat on experimental acute ocular toxoplasmosis
por: Zhang, Yu, et al.
Publicado: (2022)

HDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases
por: Yoon, Somy, et al.
Publicado: (2016)

Maspin is a PTEN-Upregulated and p53-Upregulated Tumor Suppressor Gene and Acts as an HDAC1 Inhibitor in Human Bladder Cancer
por: Lin, Yu-Hsiang, et al.
Publicado: (2019)

Comparative in vivo bioequivalence and in vitro dissolution of two valproic acid sustained-release formulations
por: Fujii, Akira, et al.
Publicado: (2009)

Inhibitory effect of valproic acid on bladder cancer in combination with chemotherapeutic agents in vitro and in vivo
por: WANG, DEGUI, et al.
Publicado: (2013)

Oral Administration of the Pimelic Diphenylamide HDAC Inhibitor HDACi 4b Is Unsuitable for Chronic Inhibition of HDAC Activity in the CNS In Vivo
por: Beconi, Maria, et al.
Publicado: (2012)

Metabolism, HDACs, and HDAC Inhibitors: A Systems Biology Perspective
por: King, Jacob, et al.
Publicado: (2021)

Rapid In Vivo Validation of HDAC Inhibitor-Based Treatments in Neuroblastoma Zebrafish Xenografts
por: Wrobel, Jagoda K, et al.
Publicado: (2020)

Cell type-specific anti-cancer properties of valproic acid: independent effects on HDAC activity and Erk1/2 phosphorylation
por: Gotfryd, Kamil, et al.
Publicado: (2010)

Valproic Acid Neuroprotection in the 6-OHDA Model of Parkinson's Disease Is Possibly Related to Its Anti-Inflammatory and HDAC Inhibitory Properties
por: Ximenes, José Christian Machado, et al.
Publicado: (2015)

Valproic Acid Inhibits Progressive Hereditary Hearing Loss in a KCNQ4 Variant Model through HDAC1 Suppression
por: Nam, Yoon Seok, et al.
Publicado: (2023)

Involvement of HDAC1 and HDAC3 in the Pathology of Polyglutamine Disorders: Therapeutic Implications for Selective HDAC1/HDAC3 Inhibitors
por: Thomas, Elizabeth A.
Publicado: (2014)

Anticancer effects of valproic acid on oral squamous cell carcinoma via SUMOylation in vivo and in vitro
por: Sang, Zhijian, et al.
Publicado: (2016)

Continuous Activity Assay for HDAC11 Enabling Reevaluation of HDAC Inhibitors
por: Kutil, Zsófia, et al.
Publicado: (2019)

The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo
por: Booth, Laurence, et al.
Publicado: (2017)

A Dual PI3K/HDAC Inhibitor Downregulates Oncogenic Pathways in Hematologic Tumors In Vitro and In Vivo
por: Yan, Zheng, et al.
Publicado: (2021)

Disruption of Planar Cell Polarity Pathway Attributable to Valproic Acid-Induced Congenital Heart Disease through Hdac3 Participation in Mice
por: Duan, Hong-Yu, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_qu5bv21kftal6kqrt0e03j6s4a